Subarachnoid Hemorrhage Medication

  • Author: Tibor Becske, MD; Chief Editor: Helmi L Lutsep, MD   more...
 
Updated: Oct 20, 2011
 

Medication Summary

The goals of treatment in patients with subarachnoid hemorrhage (SAH) are as follows:

  • Blood pressure control
  • Prevention of seizures
  • Treatment of nausea
  • Management of intracranial pressure
  • Prevention of vasospasm
  • Control of pain
  • Maintenance of cerebral perfusion

Medications used for these purposes include analgesics, calcium channel blockers, antiepileptic drugs, stool softeners, antihypertensive agents, antiemetics, osmotic agents, diuretics, and general anesthetics. The use of aminocaproic acid for hemostasis is controversial.

Next

Opioid Analgesics

Class Summary

Pain control is essential to quality patient care. It ensures patient comfort and promotes pulmonary toilet. Most analgesics have sedating properties that benefit patients who experience pain.

Fentanyl citrate (Actiq, Abstral, Onsolis, Fentora, Duragesic)

 

Fentanyl is a synthetic opioid that is 75-200 times more potent than morphine sulfate and has a much shorter half-life. It has less of a hypotensive effect and is safer in patients with hyperactive airway disease than morphine because of minimal to no associated histamine release. By itself, fentanyl causes little cardiovascular compromise, although the addition of benzodiazepines or other sedatives may result in decreased cardiac output and blood pressure.

Consider giving fentanyl by continuous infusion because of its short half-life. The parenteral form is the drug of choice for conscious sedation analgesia. It is ideal for analgesic action of short duration during anesthesia and the immediate postoperative period. It is also an excellent choice for pain management and sedation, with its short duration (30-60 min) and easy titration. After the initial parenteral dose, subsequent parenteral doses should not be titrated more frequently than every 3 or 6 hours.

The transdermal form of fentanyl is used only for chronic pain conditions in opioid-tolerant patients. When using the transdermal dosage form, most patients are controlled with 72-hour dosing intervals; however, some patients require dosing intervals of 48 hours.

The effects of fentanyl are easily and quickly reversed by naloxone. Fentanyl is highly lipophilic and protein bound. Prolonged exposure leads to accumulation in fat and delays the weaning process.

Previous
Next

Calcium Channel Blockers

Class Summary

In specialized conducting and automatic cells in the heart, calcium is involved in the generation of the action potential. The calcium channel blockers inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity. These agents may attenuate deleterious effects of calcium influx in patients with acute neurotrauma.

Nimodipine

 

Nimodipine is indicated to reduce poor outcome related to aneurysmal subarachnoid hemorrhage.[26] While studies have shown benefit regarding severity of neurologic deficits caused by cerebral vasospasm following SAH, no evidence exists that nimodipine either prevents or relieves spasms of cerebral arteries. Thus, the actual mechanism of action is unknown.

Begin therapy within 96 hours of SAH. Nimodipine is given orally. If the patient cannot swallow the capsule because he or she is undergoing surgery or unconscious, make holes at both ends of the capsule with an 18-gauge needle and extract the contents into a syringe, empty the contents into the patient's in situ nasogastric tube, and wash it down the tube with 30 mL of isotonic saline.

Previous
Next

Anticonvulsants, Other

Class Summary

These agents prevent seizure recurrence and terminate clinical and electrical seizure activity. The use of antiepileptic drugs in patients with SAH who have not had seizures is controversial and depends on the individual preference of the neurosurgeon; they usually are used only in patients who have had seizures. Conventional loading doses may be used.

Phenytoin (Dilantin, Phenytek)

 

Phenytoin may act in the motor cortex, where it may inhibit spread of seizure activity. The activity of brainstem centers responsible for the tonic phase of grand mal seizures also may be inhibited. The dose should be individualized. If the daily dose cannot be divided equally, administer the larger portion at bedtime.

Phenobarbital

 

Phenobarbital elevates the seizure threshold and limits the spread of seizure activity; it also has sedative properties.

Fosphenytoin (Cerebyx)

 

Fosphenytoin is a diphosphate ester salt of phenytoin that acts as a water-soluble prodrug of phenytoin; plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin; phenytoin, in turn, stabilizes neuronal membranes and decreases seizure activity.

The dose of fosphenytoin is expressed as phenytoin equivalents (PE), to avoid the need to perform molecular weight–based adjustments when converting between fosphenytoin and phenytoin sodium doses.

Fosphenytoin is intended for parenteral administration. Intravenous use is the route of choice and should be used in emergency situations.

Previous
Next

Stool Softeners

Class Summary

These agents prevent elevation of intracranial pressure from the Valsalva maneuver.

Docusate sodium (Colace, Correctol, Dok)

 

Docusate is an anionic surfactant used for patients who should avoid straining during defecation. This agent allows incorporation of water and fat into stool, causing stool to soften. It has minimal laxative effect.

Senna (Senokot, Ex-Lax, Senexon, SennaGen)

 

Senna is an anthraquinone stimulant hydrolyzed by colonic bacteria into an active compound. It is more potent than cascara sagrada and produces considerably more abdominal pain. Senna usually produces action 8-12 hours after administration.

Previous
Next

Beta-Blockers, Alpha Activity

Class Summary

In patients who have suffered SAH from a ruptured aneurysm, these agents are used to maintain blood pressure in a range that allows for sufficient cerebral perfusion yet limits the risk of rebleeding from elevated ICP.

Labetalol (Trandate)

 

Labetalol blocks alpha-, beta1-, and beta2-adrenergic receptor sites, decreasing blood pressure.

Previous
Next

Antiemetic Agents

Class Summary

These agents are used for the treatment of nausea or vomiting.

Promethazine (Phenergan, Phenadoz, Promethegan)

 

Promethazine is an antidopaminergic agent effective in the treatment of emesis. It blocks postsynaptic mesolimbic dopaminergic receptors in the brain and reduces stimuli to the brainstem reticular system.

Previous
Next

Diuretics, Osmotic Agents

Class Summary

These agents are used in an attempt to lower ICP and cerebral edema by creating an osmotic gradient across an intact blood-brain barrier; as water diffuses from the brain into the intravascular compartment, ICP decreases.

Mannitol (Osmitrol, Aridol)

 

Mannitol may reduce pressure within the subarachnoid space by creating an osmotic gradient between the CSF in the arachnoid space and the plasma. This agent is not for long-term use.

Previous
Next

Diuretics, Loop

Class Summary

These agents are used to decrease plasma volume and edema by causing diuresis.

Furosemide (Lasix)

 

Furosemide is used in the acute setting for reduction of increased ICP. Doses must be individualized. The proposed mechanisms in lowering ICP include the following:

• Suppression of cerebral sodium uptake

• Inhibition of carbonic anhydrase, resulting in decreased CSF production

• Inhibition of the cellular membrane cation-chloride pump, thereby affecting transport of water into astroglial cells

Previous
Next

Hemostatics

Class Summary

These agents are potent inhibitors of fibrinolysis and can reverse states that are associated with excessive fibrinolysis. Their use is controversial; consultation with admitting physicians is urged prior to use.

Aminocaproic acid (Amicar)

 

Aminocaproic acid inhibits fibrinolysis via inhibition of plasminogen activator substances and, to a lesser degree, through antiplasmin activity. The main problems with its use are that thrombi that form during treatment are not lysed and its effectiveness is uncertain. This agent has been used to prevent recurrence of SAH.

Previous
Next

General Anesthetics, Systemic

Class Summary

These agents provide sedation when neuromuscular blocking agents are used for intubation.

Thiopental

 

Thiopental is a short-acting barbiturate sedative-hypnotic with rapid onset and a duration of action of 5-20 minutes. Like methohexital, it is most commonly used as an induction agent for intubation.

Thiopental depresses consciousness and diminishes or terminates seizure effects; it facilitates transmission or impulses from the thalamus to the cortex of the brain, resulting in an imbalance in central inhibitory and facilitating mechanisms. To use thiopental as a sedative, titrate in dosage increments of 25 mg (adjust to lower dose in children).

Etomidate (Amidate)

 

Amidate is a nonbarbiturate imidazole compound with sedative properties. It is short-acting and has a rapid onset of action; the duration of action is dose dependent (15-30 minutes). Its most useful feature as an induction agent is that it produces deep sedation while causing minimal cardiovascular effects.

The major application of amidate is induction for endotracheal intubation, particularly in patients with, or at risk for, hemodynamic compromise. Amidate has been shown to depress adrenal cortical function; however, this effect is not significant clinically during short-term administration. Since the drug is mixed in propylene glycol, continuous infusion not recommended.

Previous
Next

Anxiolytics, Benzodiazepines

Class Summary

By binding to specific receptor sites, these agents appear to potentiate the effects of gamma-aminobutyrate (GABA) and to facilitate inhibitory GABA neurotransmission, as well as other inhibitory transmitters.

Midazolam

 

Midazolam is a shorter-acting benzodiazepine sedative-hypnotic that is useful in patients requiring acute or short-term sedation. It is also useful for its amnestic effects.

Previous
 
Contributor Information and Disclosures
Author

Tibor Becske, MD  Clinical Assistant Professor, Departments of Radiology and Neurology, Langone Medical Center, New York University School of Medicine; Assistant Attending Physician, Departments of Radiology and Neurology, Bellevue Hospital Center

Tibor Becske, MD is a member of the following medical societies: Society of NeuroInterventional Surgery and Society of Vascular and Interventional Neurology (SVIN)

Disclosure: ev3 reimbursement of expenses and proctoring honoraria Independent contractor

Coauthor(s)

George I Jallo, MD  Professor of Neurosurgery, Pediatrics, and Oncology, Director, Clinical Pediatric Neurosurgery, Department of Neurosurgery, Johns Hopkins University School of Medicine

George I Jallo, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, and American Society of Pediatric Neurosurgeons

Disclosure: Codman (Johnson & Johnson) Grant/research funds Consulting; Medtronic Grant/research funds Consulting

Chief Editor

Helmi L Lutsep, MD  Professor, Department of Neurology, Oregon Health and Science University School of Medicine; Associate Director, Oregon Stroke Center

Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association

Disclosure: Co-Axia Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Concentric Medical Consulting fee Review panel membership

Additional Contributors

Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Howard S Kirshner, MD Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center

Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. McCormack RF, Hutson A. Can computed tomography angiography of the brain replace lumbar puncture in the evaluation of acute-onset headache after a negative noncontrast cranial computed tomography scan?. Acad Emerg Med. Apr 2010;17(4):444-51. [Medline].

  2. Marden FA, Roy SS. Endovascular management of intracerebral and subarachnoid hemorrhage. Curr Treat Options Cardiovasc Med. Jul 2005;7(3):197-209. [Medline].

  3. Park YS, Suk JS, Kwon JT. Repeated rupture of a middle meningeal artery aneurysm in moyamoya disease. J Neurosurg. Dec 11 2009;[Medline].

  4. van der Velden LB, Otterspoor LC, Schultze Kool LJ, Biessels GJ, Verheugt FW. Acute myocardial infarction complicating subarachnoid haemorrhage. Neth Heart J. Aug 2009;17(7-8):284-7. [Medline].

  5. Morris PG, Wilson JT, Dunn L. Anxiety and depression after spontaneous subarachnoid hemorrhage. Neurosurgery. Jan 2004;54(1):47-52; discussion 52-4. [Medline].

  6. Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. Nov 1 2005;112(18):2851-6. [Medline].

  7. [Best Evidence] Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. Aug 2010;41(8):e519-36. [Medline].

  8. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Lee JS, Eisenhauer M. High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ. 2010;341:c5204. [Medline].

  9. Lin CL, Dumont AS, Lieu AS, et al. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. Dec 2003;99(6):978-85. [Medline].

  10. Becker H. Consequences of a Nonrecognized Subarachnoid Hemorrhage. Klin Neuroradiol. Nov 20 2009;[Medline].

  11. Schuiling WJ, Dennesen PJ, Tans JT, Kingma LM, Algra A, Rinkel GJ. Troponin I in predicting cardiac or pulmonary complications and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. Nov 2005;76(11):1565-9. [Medline]. [Full Text].

  12. Jeon IC, Chang CH, Choi BY, Kim MS, Kim SW, Kim SH. Cardiac troponin I elevation in patients with aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. Aug 2009;46(2):99-102. [Medline]. [Full Text].

  13. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. Jan 26 2006;354(4):387-96. [Medline].

  14. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Emond M, Symington C, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ. Jul 18 2011;343:d4277. [Medline]. [Full Text].

  15. Boesiger BM, Shiber JR. Subarachnoid hemorrhage diagnosis by computed tomography and lumbar puncture: are fifth generation CT scanners better at identifying subarachnoid hemorrhage?. J Emerg Med. Jul 2005;29(1):23-7. [Medline].

  16. Goddard AJ, Tan G, Becker J. Computed tomography angiography for the detection and characterization of intra-cranial aneurysms: current status. Clin Radiol. Dec 2005;60(12):1221-36. [Medline].

  17. Jayaraman MV, Mayo-Smith WW, Tung GA, et al. Detection of intracranial aneurysms: multi-detector row CT angiography compared with DSA. Radiology. Feb 2004;230(2):510-8. [Medline].

  18. Maslehaty H, Petridis AK, Barth H, Mehdorn HM. Diagnostic value of magnetic resonance imaging in perimesencephalic and nonperimesencephalic subarachnoid hemorrhage of unknown origin. J Neurosurg. Apr 2011;114(4):1003-7. [Medline].

  19. Koivisto T, Vanninen R, Hurskainen H, Saari T, Hernesniemi J, Vapalahti M. Outcomes of early endovascular versus surgical treatment of ruptured cerebral aneurysms. A prospective randomized study. Stroke. Oct 2000;31(10):2369-77. [Medline].

  20. Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. Oct 26 2002;360(9342):1267-74. [Medline].

  21. [Best Evidence] Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. Sep 3-9 2005;366(9488):809-17. [Medline].

  22. Qureshi AI, Vazquez G, Tariq N, Suri MF, Lakshminarayan K, Lanzino G. Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States. Clinical article. J Neurosurg. Mar 2011;114(3):834-41. [Medline].

  23. O'Kelly CJ, Kulkarni AV, Austin PC, Wallace MC, Urbach D. The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: an administrative data analysis. J Neurosurg. Oct 23 2009;[Medline].

  24. Whitfield PC, Kirkpatrick PJ. Timing of surgery for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2001;CD001697. [Medline].

  25. Koffijberg H, Rinkel GJ, Buskens E. Aneurysm Occlusion in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Cost-Utility Analysis. J Neurol Neurosurg Psychiatry. Dec 3 2009;[Medline].

  26. [Guideline] Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. Mar 2009;40(3):994-1025. [Medline].

  27. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. Mar 17 1983;308(11):619-24. [Medline].

  28. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. Mar 11 1989;298(6674):636-42. [Medline]. [Full Text].

  29. [Best Evidence] Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. Aug 2005;36(8):1627-32. [Medline].

  30. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke. Sep 2005;36(9):2024-6. [Medline].

  31. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke. Sep 2008;39(9):2622-6. [Medline].

  32. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. Jan 2010;41(1):e47-52. [Medline].

  33. Sandercock P. 'Yes' or 'no' to routine statins after subarachnoid hemorrhage to prevent delayed cerebral ischaemia, vasospasm, and death? A cautionary tale of 2 meta-analyses. Stroke. Jan 2010;41(1):e1-2. [Medline].

  34. Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care. 2010;14(1):R23. [Medline]. [Full Text].

  35. Elliott JP, Newell DW, Lam DJ, et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. Feb 1998;88(2):277-84. [Medline].

  36. Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. May 2010;38(5):1284-90. [Medline].

  37. Ma L, Liu WG, Zhang JM, Chen G, Fan J, Sheng HS. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials. Brain Inj. 2010;24(5):730-5. [Medline].

  38. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. May 2010;41(5):921-6. [Medline].

  39. Gomis P, Graftieaux JP, Sercombe R, Hettler D, Scherpereel B, Rousseaux P. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. Mar 2010;112(3):681-8. [Medline].

  40. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. Feb 17 2010;CD006778. [Medline].

  41. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neuroradiology. Sep 2010;52(9):837-45. [Medline].

  42. Hughes PD, Becker GJ. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease. Nephrology (Carlton). Aug 2003;8(4):163-70. [Medline].

  43. Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. Oct 31 2000;102(18):2300-8. [Medline].

  44. Wermer MJ, Koffijberg H, van der Schaaf IC. Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage. Neurology. May 27 2008;70(22):2053-62. [Medline].

Previous
Next
 
CT scan reveals subarachnoid hemorrhage in the right sylvian fissure; no evidence of hydrocephalus is apparent.
CT scan reveals subarachnoid hemorrhage in the sylvian fissure, right more than left.
A 47-year-old woman presented with headache and vomiting; her CT scan in the emergency department revealed subarachnoid hemorrhage.
Cerebral angiogram reveals a middle cerebral artery aneurysm.
Cerebral angiogram reveals a middle cerebral artery aneurysm.
Cerebral angiogram (lateral view) reveals a large aneurysm arising from the left anterior choroidal artery.
Cerebral angiogram (anteroposterior view) reveals a large aneurysm arising from the left anterior choroidal artery.
Brain CT scan showing subtle finding of blood at the area of the circle of Willis consistent with acute subarachnoid hemorrhage. Image courtesy of Dana Stearns, MD, Massachusetts General Hospital.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.